Christopher Mackintosh, MLA; Chen Yuan, ScD; Fang-Shu Ou, PhD; et al.
free access
JAMA Oncol. 2020;6(11):1713-1721. doi:10.1001/jamaoncol.2020.3938
This cohort study evaluates the association of coffee consumption with disease progression and death in patients with advanced or metastatic colorectal cancer.
-
Invited Commentary
Coffee and Colorectal Cancer: Is Improved Survival a 鈥淧erk鈥� of Coffee Drinking?
Erikka Loftfield, PhD, MPH; Marc J. Gunter, PhD; Rashmi Sinha, PhD
JAMA Oncol
Christopher R. Manz, MD; Jinbo Chen, PhD; Manqing Liu, MHS; et al.
free access
JAMA Oncol. 2020;6(11):1723-1730. doi:10.1001/jamaoncol.2020.4331
This prognostic study uses data from patients with outpatient medical or gynecologic oncology encounters to investigate the validity of a machine learning algorithm to predict patient 180-day mortality.
Stijn van Roessel, MD, MSc; Eran van Veldhuisen, BSc; Sjors Klompmaker, MD, MSc, PhD; et al.
free access
JAMA Oncol. 2020;6(11):1733-1740. doi:10.1001/jamaoncol.2020.3537
This cohort study uses data from an existing cohort of patients undergoing resection of pancreatic cancer to assess the overall survival of patients treated with neoadjuvant FOLFIRINOX after surgery for pancreatic ductal adenocarcinoma.
Ranjan Pathak, MD, MHS; Sarah B. Goldberg, MD, MPH; Maureen Canavan, PhD, MPH; et al.
free access
has audio
JAMA Oncol. 2020;6(11):1741-1750. doi:10.1001/jamaoncol.2020.4232
This cohort study uses data from the National Cancer Database to assess the association between adjuvant chemotherapy and survival in patients with node-negative early-stage non鈥搒mall cell lung cancer (NSCLC) with vs without high-risk pathologic features.
-
Podcast:
Survival and Adjuvant Chemotherapy in Early-Stage NSCLC With vs Without Clinicopathologic Features
Srikala S. Sridhar, MD; Normand Blais, MD; Ben Tran, MD; et al.
free access
JAMA Oncol. 2020;6(11):1751-1758. doi:10.1001/jamaoncol.2020.3927
This randomized clinical trial evaluates the efficacy and safety of nab-paclitaxel vs paclitaxel in patients with platinum-refractory metastatic urothelial cancer.
Smith Giri, MD, MHS; Alyssa Grimshaw, MSLIS; Susan Bal, MD; et al.
free access
JAMA Oncol. 2020;6(11):1759-1765. doi:10.1001/jamaoncol.2020.4338
This systematic review and meta-analysis assesses the association of the addition of daratumumab to backbone multiple myeloma regimens with progression-free survival among patients with cytogenetically defined high-risk multiple myeloma.
Ana Oaknin, MD, PhD; Anna V. Tinker, MD; Lucy Gilbert, MD; et al.
open access
JAMA Oncol. 2020;6(11):1766-1772. doi:10.1001/jamaoncol.2020.4515
This open-label phase 1 study assesses the antitumor activity, tolerability, and safety of dostarlimab for patients with recurrent or advanced deficient mismatch repair endometrial cancer that has progressed after platinum-containing chemotherapy.
Douglas W. Blayney, MD; Qingyuan Zhang, MD; Jifeng Feng, MD; et al.
free access
online only
JAMA Oncol. 2020;6(11):e204429. doi:10.1001/jamaoncol.2020.4429
This randomized phase 2 clinical trial assesses the efficacy and safety of plinabulin compared with pegfilgrastim for the prevention of chemotherapy-induced neutropenia following docetaxel chemotherapy in adult patients with non鈥搒mall lung cancer.
Thomas Yau, MD; Yoon-Koo Kang, MD; Tae-You Kim, MD; et al.
open access
online only
JAMA Oncol. 2020;6(11):e204564. doi:10.1001/jamaoncol.2020.4564
This randomized clinical trial assesses the efficacy of nivolumab plus ipilimumab in the treatment of patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib.